Document:

inqd_ex102.htm

EXHIBIT 10.2
 
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
 
COMMON STOCK PURCHASE WARRANT
 
INDOOR HAVEST CORP
 
Warrant Shares: 250,000 
Issue Date: 9/26/2016
 
THIS COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies that, for value received, Chuck Rifici Holdings, Inc. (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the "Initial Exercise Date") and on or prior to the close of business on the one (1) year anniversary of the Initial Exercise Date (the "Termination Date") but not thereafter, to subscribe for and purchase from Indoor Harvest Corp, a Texas corporation (the "Company"), up to Two Hundred Fifty Thousand (250,000) shares (the "Warrant Shares") of Company common stock (the "Common Stock"). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
 
	1.	Purchase of Shares. Subject to the terms and conditions hereinafter set forth, the holder of this Warrant is entitled, upon surrender of this Warrant at the principal office of the Company (or at such other place as the Company shall notify the holder hereof in writing), to purchase from the Company up to one fully paid and non assessable shares of the Company’s Common Stock (each a “Share” and collectively the “Shares”) at an exercise price of $0.30 per Share (such price, as adjusted from time to time, is herein referred to as the “Exercise Price”).
	 
	 

	2.	Exercise Period. This Warrant shall be exercisable, in whole or in part, during the term commencing on the issuance date of this Warrant, for a period of one year, ending at 5 p.m. Texas time on (the “Exercise Period”).
	 
	 

	3.	Method of Exercise. While this Warrant remains outstanding and exercisable in accordance with Section 2 above, the holder may exercise from time to time, in whole or in part, the purchase rights evidenced hereby. Such exercise shall be effected by:

 
	 
	(i)	the surrender of the Warrant, together with a notice of exercise to the Secretary of the Company at its principal offices; and
	 
	 
	 

	 
	(ii)	the payment to the Company of an amount equal to the aggregate Exercise Price for the number of Shares being purchased.

 
	4.	Certificates for Shares; Amendments of Warrants. Upon the exercise of the purchase rights evidenced by this Warrant, one or more certificates for the number of Shares so purchased shall be issued as soon as practicable thereafter, and in any event within thirty (30) days of the delivery of the subscription notice. Upon partial exercise, the Company shall promptly issue an amended Warrant representing the remaining number of Shares purchasable thereunder. All other terms and conditions of such amended Warrant shall be identical to those contained herein.

	 
	1

	

	 

 
	5.	Issuance of Shares. The Company covenants that (i) the Shares, when issued pursuant to the exercise of this Warrant, will be duly and validly issued, fully paid and non assessable and free from all taxes, liens, and charges with respect to the issuance thereof, (ii) during the Exercise Period the Company will reserve from its authorized and unissued Common Stock sufficient Shares in order to perform its obligations under this warrant.
	 
	 

	6.	Adjustment of Exercise Price and Number of Shares. The number of and kind of securities purchasable upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows:

    
	 
	(a)	Subdivisions, Combinations and Other Issuances. If the Company shall at any time before the expiration of this Warrant subdivide the Shares, by split-up or otherwise, or combine its Shares, or issue additional shares of its Shares as a dividend, the number of Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the purchase price payable per share, but the aggregate purchase price payable for the total number of Shares purchasable under this Warrant (as adjusted) shall remain the same. Any adjustment under this Section 6 shall become effective at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record date is fixed, upon the making of such dividend.
	 
	 
	 

	 
	(b)	Reclassification, Reorganization and Consolidation. In case of any reclassification, capital reorganization, or change in the capital stock (including because of a change of control) of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section 6(a) above), then the Company shall make appropriate provision so that the holder of this Warrant shall have the right at any time before the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this Warrant, the kind and amount of shares of stock and other securities and property receivable in connection with such reclassification, reorganization, or change by a holder of the same number of Shares as were purchasable by the holder of this Warrant immediately before such reclassification, reorganization, or change. In any such case appropriate provisions shall be made with respect to the rights and interest of the holder of this Warrant so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon exercise hereof, and appropriate adjustments shall be made to the purchase price per share payable hereunder, provided the aggregate purchase price shall remain the same.
	 
	 
	 

	 
	(c)	Notice of Adjustment. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise of the Warrant, or in the Exercise Price, the Company shall promptly notify the holder of such event and of the number of Shares or other securities or property thereafter purchasable upon exercise of this Warrant.

 
	7.	No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise Price then in effect.
	 
	 

	8.	Representations of the Company. The Company represents that all corporate actions on the part of the Company, its officers, directors and stockholders necessary for the sale and issuance of this Warrant have been taken.

	 
	2

	

	 

 
	9.	Representations and Warranties by the Holder. The Holder represents and warrants to the Company as follows:

    
	 
	(a)	This Warrant and the Shares issuable upon exercise thereof are being acquired for its own account, for investment and not with a view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act of 1933, as amended (the “Act”). Upon exercise of this Warrant, the Holder shall, if so requested by the Company, confirm in writing, in a form satisfactory to the Company, that the securities issuable upon exercise of this Warrant are being acquired for investment and not with a view toward distribution or resale.
	 
	 
	 

	 
	(b)	The Holder understands that the Warrant and the Shares have not been registered under the Act by reason of their issuance in a transaction exempt from the registration and prospectus delivery requirements of the Act pursuant to Section 4(2) thereof, and that they must be held by the Holder indefinitely, and that the Holder must therefore bear the economic risk of such investment indefinitely, unless a subsequent disposition thereof is registered under the Act or is exempted from such registration. 
	 
	 
	 

	 
	(c)	The Holder has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the purchase of this Warrant and the Shares purchasable pursuant to the terms of this Warrant and of protecting its interests in connection therewith.
	 
	 
	 

	 
	(d)	The Holder is able to bear the economic risk of the purchase of the Shares pursuant to the terms of this Warrant.
	 
	 
	 

	 
	(e)	The Holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Act.

 
	10.	Restrictive Legend.

 
The Shares (unless registered under the Act) shall be stamped or imprinted with a legend in substantially the following form:
 
	 
	(i)	THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). SUCH SECURITIES MAY NOT BE TRANSFERRED UNLESS A REGISTRATION STATEMENT UNDER THE ACT IS IN EFFECT AS TO SUCH TRANSFER OR SUCH TRANSFER MAY BE MADE PURSUANT TO RULE 144 OR IN THE OPINION OF COUNSEL FOR THE COMPANY, REGISTRATION UNDER THE ACT IS UNNECESSARY IN ORDER FOR SUCH TRANSFER TO COMPLY WITH THE ACT.
	 
	 
	 

	 
	(ii)	THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN AN AMENDED AND RESTATED VOTING AGREEMENT AND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH IS AVAILABLE UPON REQUEST FROM THE COMPANY. THESE TRANSFER RESTRICTIONS ARE BINDING UPON ALL TRANSFEREES OF THE SECURITIES. THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED FOR A PERIOD NOT TO EXCEED 180 DAYS FOLLOWING THE EFFECTIVE DATE OF A REGISTRATION STATEMENT FILED BY THE COMPANY FOR ITS INITIAL PUBLIC OFFERING IF REQUESTED BY THE UNDERWRITERS IN ACCORDANCE WITH SUCH AGREEMENT.

 
	 
	3

	

	 

 
	11.	Warrants Transferable. Subject to compliance with the terms and conditions of this Section 11, this Warrant and all rights hereunder are transferable, without charge to the holder hereof (except for transfer taxes), upon surrender of this Warrant properly endorsed or accompanied by written instructions of transfer. With respect to any offer, sale or other disposition of this Warrant or any Shares acquired pursuant to the exercise of this Warrant before registration of such Warrant or Shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if requested by the Company, to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or the Shares and indicating whether or not under the Act certificates for this Warrant or the Shares to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, if so requested, the Company, as promptly as practicable, shall notify such holder that such holder may sell or otherwise dispose of this Warrant or such Shares, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 11 that the opinion of counsel for the holder or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such determination has been made. Each certificate representing this Warrant or the Shares transferred in accordance with this Section 11 shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the aforesaid opinion of counsel for the holder, such legend is not required. In order to ensure compliance with such laws, the Company may issue stop transfer instructions to its transfer agent in connection with such restrictions.
	 
	 

	12.	Rights of Stockholders. No holder of this Warrant shall be entitled, as a Warrant holder, to vote or receive dividends or be deemed the holder of the Shares or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until the Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.
	 
	 

	13.	Notices. All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall in any event be deemed to be given upon receipt or, if earlier, (a) five (5) days after deposit with the U.S. Postal Service or other applicable postal service, if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) one business day after the business day of deposit with Federal Express or similar overnight courier, freight prepaid or (d) one business day after the business day of facsimile transmission, if delivered by facsimile transmission with copy by first class mail, postage prepaid, and shall be addressed (i) if to the Holder, at the Holder’s address as set forth on the Schedule of Investors to the Note Purchase Agreement, and (ii) if to the Company, at the address of its principal corporate offices (attention: President), or at such other address as a party may designate by ten days advance written notice to the other party pursuant to the provisions above.
	 
	 

	14.	Governing Law. This Warrant and all actions arising out of or in connection with this Agreement shall be governed by and construed in accordance with the laws of Texas, without regard to the conflicts of law provisions of Texas or of any other state.
	 
	 

	15.	Rights and Obligations Survive Exercise of Warrant. Unless otherwise provided herein, the rights and obligations of the Company, of the holder of this Warrant and of the holder of the Shares issued upon exercise of this Warrant, shall survive the exercise of this Warrant.

  
IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.
 
 
	INDOOR HARVEST CORP
	
	 	 	 
	By:	/s/ Chad Sykes	
	 
	Chad Sykes, CEO	 

 
	 
	4

	

	 

  
NOTICE OF EXERCISE
 
TO: INDOOR HARVEST CORP
 
(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.
 
(2) Payment shall take the form of lawful money of the United States;
 
(3) Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:
 
_______________________________
 
The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:
 
_______________________________
 
_______________________________
 
_______________________________
 
(4) Accredited Investor. The undersigned is an "accredited investor" as defined in Regulation D promulgated under the Securities Act of 1933, as amended.
 
 
[SIGNATURE OF HOLDER]
 
Name of Investing Entity:  _______________________________________________________________________
Signature of Authorized Signatory of Investing Entity: _________________________________________________
Name of Authorized Signatory:  ___________________________________________________________________
Title of Authorized Signatory: ____________________________________________________________________
Date: _______________________________________________________________________________________
 
	 
	5

	

	 

 
ASSIGNMENT FORM
 
(To assign the foregoing warrant, execute
this form and supply required information.
Do not use this form to exercise the warrant.)
 
FOR VALUE RECEIVED, [___] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to
 
_______________________________________________ whose address is ______________________________________________________________.
 
 
______________________________________________________________
 
Dated: _______________, _______
 
Holder's Signature:  _________________________________
 
Holder's Address: __________________________________
 
   __________________________________
 
Signature Guaranteed:  ___________________________________________
 
NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.
 
 
	6Exhibit 10.60

 

 

 

 

ENGAGEMENT LETTER

 

This consulting Agreement (“Agreement”)
is entered into as of the 2nd  day of March, 2016 (“Effective Date”), by and among Aeon Clinical
Laboratories (“Aeon”), with address at 2225 Centennial Drive, Gainesville, GA 30504, and Windham Brannon, P.C.
(Windham Brannon” or “the Firm”).

 

Background

 

Aeon and Windham Brannon wish to memorialize
a business relationship whereby the Firm will perform certain services for Aeon in accordance with the terms and conditions of
this Agreement.

 

For and in consideration of the mutual
covenants described below, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follow:

 

1.     Duties.
Windham Brannon agrees to provide services as described in one or more statements of work in the form attached hereto as Schedule
A that are executed by the Firm and the authorized representative of Aeon (each, a “SOW”). The services
described in each SOW are referred to herein as the “Services”. The SOWs are incorporated herein and made a
part of this Agreement. The Firm agrees that the Firm shall serve Aeon faithfully, to the best of the Firm’s ability and
devote a sufficient amount of time to Aeon’s business affairs.

 

2.     Fees.
Windham Brannon shall perform the Services for the professional fees set forth in each SOW. The initial SOW is attached hereto
as Schedule A. Unless otherwise specified in the Statement of Work, the Firm shall submit invoices for Services rendered
at the beginning of each month. Aeon agrees to pay all correct and undisputed invoices upon receipt. Invoices outstanding for more
than 30 days shall be subject to a service charge of 1.5% per month.

 

3.     Expenses.
Any necessary out-of-pocket expenses will be invoiced to Aeon Clinical Laboratories, without markup. These expenses will be subject
to same payment terms of professional fees. All expenses will receive prior approval from Aeon wherever possible.

 

4.     Term
and Termination. The term of this Agreement shall continue from its Effective Date until this Agreement is terminated or canceled
as provided hereunder.

 

5.     Materials.
 Upon termination of this Agreement for any reason or upon request by Aeon, the Firm shall return immediately all documents,
property, and other records and all copies thereof, within the Firm’s possession, custody or control, including, but not
limited to, any materials containing any Work Product (as defined below), Trade Secrets (as defined below) or Confidential Information
(as defined below) or any portion thereof.

 

6.     Ownership.
For purposes of this Agreement, “Work Product” means the data, materials, documentation, computer programs,
inventions (whether or not patentable), pictures, audio, video, animations, artistic works, and all works of authorship, including
all worldwide rights therein under patent, copyright, trade secret, confidential information, or other property right, created
or developed in whole or in part by the Firm after the Effective Date and that either (i) is created within the scope of the Services,
or (ii) has been or will be paid for by Aeon. Aeon shall own all rights in and to the Work Product, including, but not limited
to, copyrights, patent rights, moral rights and trade secret rights. All pre-existing Work Products owned and licensed by Windham
Brannon prior to the Effective Date of this Agreement shall remain the Firm’s Work Product. The Firm retains its rights to
maintain a copy of the Work Product for its records.

 

 

     

     

    

 

7.     License
to Aeon. To the extent that any pre-existing materials are contained in the materials Windham Brannon delivers to Aeon or its
customers, and such pre-existing materials are not Work Product (such pre-existing materials are referred to herein as the “Licensed
Materials”), the Firm grants to Aeon an irrevocable, nonexclusive, worldwide, license to: (i) use and distribute (internally
or externally) copies of, and prepare derivative works based upon, such pre-existing materials and derivative works thereof and
(ii) authorize others to do any of the foregoing only for the specific customer for which said materials are delivered.

 

8.     Warranties.
The Firm warrants that the Services shall be performed in a workmanlike and professional manner in accordance with applicable industry
standards. Windham Brannon warrants that the Work Product and Licensed Materials, in whole or in part, are not confidential to
the Firm or any third party.

 

9.     Confidential
Information. Each party may disclose to the other party certain Confidential Information (defined below). Both parties acknowledge
and agree that the Confidential Information is the sole and exclusive property of party supplying the information (or a third party
providing such information) and that the party supplying the information or such third party owns all worldwide rights therein
under patent, copyright, trade secret, confidential information, or other property right. Both parties acknowledge and agree to
hold the Confidential Information in strictest confidence and not to, directly or indirectly, copy, reproduce, distribute, manufacture,
duplicate, reveal, report, publish, disclose, cause to be disclosed, or otherwise transfer the Confidential Information to any
third party, or utilize the Confidential Information for any purpose whatsoever other than as expressly contemplated by this Agreement.
With regard to Confidential Information that constitutes trade secrets under applicable law, the obligations in this Section will
continue for so long as such information constitutes a trade secret under applicable law. With regard to all other Confidential
Information, the obligations in this Section will continue for the term of this Agreement and for a period of three years thereafter.
Both parties agree to return to each other, upon request by either party, the Trade Secrets and Confidential Information and all
materials relating thereto. The foregoing obligations will not apply if and to the extent that either party provides documentation
sharing that: (i) the information was already known to the receiving party, without obligation to keep such information confidential,
at the time of receipt of the information from the sending party; (ii) the information communicated was received by the receiving
party in good faith from a third party having no obligation to keep such information confidential; or (iii) the information communicated
was publicly known at the time of receipt from the sending party. For purposes of this Agreement, “Confidential Information”
means information of either party, its licensors, suppliers, customers, or prospective licensors or customers that is of value
to its owner and is treated as confidential, including, but not limited to, future business plans, licensing strategies, advertising
campaigns, information regarding executives and employees, and the terms and conditions of this Agreement.

 

10.   Indemnification.
Each party (the “Indemnitor”) agrees to indemnify, defend and hold the other party and its directors, officers, shareholders,
employees and agents harmless (the “Indemnitees”) from and against any claims, liabilities, losses, damages (including
punitive and exemplary damages), causes of action or injuries, together with costs and expenses, including reasonable attorneys’
fees, arising out of or resulting from (i) the wrongful acts or omissions of or breaches of this Agreement by the Indemnitor; (ii)
any statements, claims, representations or warranties made by the Indemnitor, relating to the products of Aeon, the Work product,
or the Licensed Materials, other than as authorized in writing; and (iii) infringement or claim thereof of any patent, copyright,
trademark, service mark, trade name, trade secret, proprietary and/or confidential information right, and/or any other property
right of a third party arising from use of any materials or deliverables provided by the Indemnitor (including, without limitation,
in the case of the Firm, the Work Product and Licensed Materials) as authorized herein.

 

11.   Equitable Relief. Each party
to this Agreement acknowledges that a breach by the other party of any of the terms or conditions of this Agreement will result
in irrevocable harm to the non-breaching party and that the remedies at law for such breach may not adequately compensate the non-breaching
party for damages suffered. Accordingly, both parties agree that in the event of such breach, both parties shall be entitled to
injunctive relief or such other equitable remedy as a court of competent jurisdiction may provide. Nothing contained herein will
be construed to limit either party’s right to any remedies at law, including the recovery of damages for breach of this Agreement.

 

     

     

    

 

12.   Severability.
If any provision or part of any provision of this Agreement is held invalid or unenforceable by a court of competent jurisdiction,
such holding shall not affect the enforceability of any other provision or parts thereof, and all other provisions and parts thereof
shall continue in full force and effect. Windham Brannon acknowledges that its undertakings and agreements contained herein are
each severable covenants independent of one another or any other provisions or covenants of this Agreement.

 

13.   Relationship
of Parties. Windham Brannon acknowledges that the Firm is an independent contractor and that the Firm and its affiliates are
fully responsible for federal, state and local taxes, as well as workers compensation and state unemployment insurance coverage.
As an independent contractor, the Firm and its affiliates are not eligible to participate in any employee benefit program offered
by Aeon to its employees. Aeon shall have no right to control and direct Windham Brannon in regard to Services performed with respect
to this Agreement, not only as to the details and means by which an SOW is completed, but also as to the manner in which the result
is to be accomplished. Nothing herein contained shall be construed to imply a joint venture, partnership or principal-agent relationship
between Windham Brannon and Aeon, and neither party shall have the right, power or authority to obligate or bind the other in any
manner whatsoever, except as otherwise agreed in writing.

 

14.   Law
and Jurisdiction. Windham Brannon and Aeon agree that any claim or cause of action whether in law or equity, arising under
or relating to this Agreement will be brought in the courts of the State of Georgia. Windham Brannon hereby consents and submits
to personal jurisdiction of such courts, and to the extent permitted by law, hereby consent that all services of process may be
made by certified or registered mail, postage prepaid and return receipt requested. This agreement, and all the terms and provisions
herein, shall be governed by and enforced according to the laws of the State of Georgia without giving effect to any of its rules
of conflicts of law.

 

15.   Amendments;
Interpretation. This Agreement shall not be amended or modified except by a writing executed by both parties. This Agreement
shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. This Agreement
and the attached Schedules represent the entire understanding of the parties concerning the subject matter hereof and supersede
all prior communications, agreements and understandings, whether oral or written, relating to the subject matter hereof. No written
waiver will constitute, or be construed as, a waiver of any other obligation or condition of this Agreement.

 

16.   Non-solicitation.
Until the date two (2) years after the termination of this Agreement for any reason, the Firm agrees and acknowledges that neither
party shall directly or indirectly solicit or induce any employee of Aeon or cause an employee to leave his or her employment without
the permission of both parties. Both parties represents that they (i) are familiar with the foregoing covenants not to compete
and not to solicit, and (ii) are fully aware of the obligations hereunder, including, without limitation, the reasonableness of
the length of time, scope and geographic coverage of these covenants.

 

17.   Non-Assignment.
Due to the nature of this Agreement, Aeon acknowledges and understands that Tom Leahey is an affiliate of Windham Brannon in this
engagement. With this exception, Windham Brannon shall not have the right to assign the Firm’s rights or obligations under
this Agreement without the prior written consent of Aeon.

 

18.   Notices.
All communications required or otherwise provided under this Agreement shall be in writing and shall be deemed given when delivered
to the address provided below such party’s signature (as may be amended by notice, from time to time), by hand, by courier
or express mail, or by registered or certified United States mail, return receipt requested, postage prepaid.

 

19.   Counterparts.
This Agreement may be executed in one or more counterparts, each of which will for all purposes be deemed to be an original and
all of which will constitute the same instrument.

 

 

     

     

    

 

IN WITNESS WHEREOF, the parties hereto
have executed this Agreement and affixed their hands effective as of the date first above written.

 

 

	WINDHAM BRANNON, P.C.:	 	Aeon Clinical Laboratories:
	 	 	 	 	 
	/s/ Thomas P. Leahey	 	/s/ William P. Henry
	(Sign here)	 	(Sign here)
	 	 	 	 	 
	By:	Thomas P. Leahey	 	By:	William P. Henry
	 	 	 	 	 
	Title:	Principal
        & Practice Leader	 	Title:	Chief
        Operating Officer
	 	 	 	 	 
	Date:
        	March
        2, 2016	 	Date:
        	March
        2, 2016
	 	 	 	 	 
	Address:	3630 Peachtree Road, NE, Suite 600	 	Address:	2225 Centennial
        Drive, Gainesville, GA 
	 	Atlanta, GA 30326	 	 	30504

 

 

     

     

    

 

SCHEDULE A

 

 

Statement of Work

 

This Schedule is an attachment of the Engagement Letter between
Aeon Clinical Laboratories (“Aeon”) and Windham Brannon, P.C. (“Windham Brannon” or “the
Firm”) dated the 2nd day of March, 2016 (“Agreement”) and is governed by the terms and provisions
set forth in the Agreement.

 

COMPENSATION AND PAYMENT WINDHAM BRANNON:

The rate of payment for this engagement is $12,500 per month.
Partial month billing will be pro-rated as to actual days divided by the number of working days. The entire agreement will renew
at the end of each 30 day period unless terminated by Aeon. The minimum term is 90 days from the execution of this agreement.

 

 

	Reporting	Chief Operating Officer / CEO / Chairman 
	Start Date	March 2, 2016
	 	 
	Duties	
        - Development of financial
        and governance policies.

        - Development of long-term
        strategic and financial plan.

        - Assessment and development
        of overall reporting/accounting function(s).

        - Assessment and development/refinement
        of treasury function.

        - Development of appropriate
        capital plan and subsequent transaction support.

        - Assessment of potential business
        combinations and subsequent transaction support

           including target diligence.

        - Leadership in external public
        filings including Form 10K, 10Q, and 8K.

        - Review and optimization of
        QuickBooks with possible migration plan.

        - Activities
as directed by executive management.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]